Sichuan Hexie Shuangma Co (000935) Fair Value & Analysis
Financial Services · CN · Market cap 20.7B CNY
Fair value as of: Jul 25, 2026
From 10 valuation models · updated 16 days ago
Share price −13.8% over the past month.
A solid business, but screening 70% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥8.30). The favourable scenario is already priced in.
- Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder.
- For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 25, 2026.
How to read this chart
60‑month range ¥10.20 – ¥33.83 · fair‑value band ¥4.98 – ¥8.30 · the ¥22.18 price screens above the ¥6.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 25, 2026.
Analysis
Sichuan Hexie Shuangma Co (000935) currently trades at ¥22.18, while our model-based Fair Value estimate is ¥6.64, implying the stock looks roughly 70.1% overvalued today. The Quality Score stands at 61/100 (solid quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Sichuan Hexie Shuangma Co generated revenue of 1.1B CNY at a net margin of 21.0%. Revenue declined 17.7% year over year. It earns a return on equity of 3.1%. Net debt stands at 451M CNY. Fundamentals as of Jul 25, 2026
Our scenario range runs from ¥4.98 (bear case) to ¥8.30 (bull case); at ¥22.18, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 35% below its 52-week high and 31% above its 52-week low, currently below its 200-day average. For context, the median of 10 Financial Services peers we cover trades at -12% fair-value upside, at -70%, 000935 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 10 models by family
Widest divergence: Economic Profit (¥7.45) versus Growth DCF (¥2.51). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 25, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 61 · Market factors (momentum, volatility) 45
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Sichuan Hexie Shuangma Co., Ltd. engages in the manufacture and sale building material products in China. It offers cement, commercial clinker, and aggregates used for infrastructure, industrial park construction, municipal livelihood projects, commercial housing development, urban renewal, and rural revitalization.
Full company description
Sichuan Hexie Shuangma Co., Ltd. engages in the manufacture and sale building material products in China. It offers cement, commercial clinker, and aggregates used for infrastructure, industrial park construction, municipal livelihood projects, commercial housing development, urban renewal, and rural revitalization. The company is also involved in biopharmaceutical research and development and production business; and private equity investment fund management business. In addition, the company engages in peptide API research and development, and production; peptide contract customization; customized research and development, and production business; and beauty peptide research and development, and production business. Further, it offers semaglutide, liraglutide, and tilpotide targeting major chronic diseases; and invest in manufacturing and new energy industries, including photovoltaics, chip design and manufacturing, consumer electronics, intelligent equipment, industrial automation, new energy, autonomous driving, and semiconductor equipment. The company was formerly known as SICHUAN SHUANGMA CEMENT CO., Ltd and changed its name to Sichuan Hexie Shuangma Co., Ltd. in February 2022. Sichuan Hexie Shuangma Co., Ltd. was founded in 1998 and is based in Chengdu, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Sichuan Hexie Shuangma Co reported revenue of ¥1.2B in FY2025 versus ¥1.2B in FY2021, a compound −0.4%/yr. Reported net income was ¥298M in FY2025, compounding −25.9%/yr from FY2021.
000935 screens 70% overvalued. Compare with Fondul Proprietatea SA →
Peer Group
Asset Management · 973 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Asset Management median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Asset Management stocks, each showing price versus our Fair Value estimate (as of Jul 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Fondul Proprietatea SA FP | $0.0420 | $0.0800 | +90% |
| BlackRock, Inc BLK | $1,136 | $465.75 | -59% |
| Blackstone Inc BX | $124.56 | $16.35 | -87% |
| Investor AB INVEB | kr 423.70 | kr 847.40 | +100% |
| Brookfield Corporation BN | C$62.45 | C$10.12 | -84% |
| KKR & Co KKR | $100.94 | $44.88 | -56% |
| AB Industrivärden INDUA | kr 532.50 | kr 1,065 | +100% |
| Jio Financial Services Limited JIOFIN | ₹242.98 | ₹40.19 | -83% |
| Hedef Holding HEDEF | 267.25 TRY | 320.98 TRY | +20% |
| Bajaj Holdings BAJAJHLDNG | ₹10,398 | ₹9,202 | -12% |
Compare Sichuan Hexie Shuangma Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is Sichuan Hexie Shuangma Co (000935) overvalued or undervalued?
What is the fair value of 000935?
What is the quality score of 000935?
What is the revenue of Sichuan Hexie Shuangma Co (000935)?
What is the net profit margin of 000935?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Sichuan Hexie Shuangma Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.